Quarterly ResultMay 6, 2026, 09:07 AM
Royalty Pharma Q1 Net Income +23% to $294.7M; EPS $0.67
AI Summary
Royalty Pharma plc reported a strong first quarter for 2026, with net income attributable to the company increasing by 23.1% to $294.7 million and basic earnings per share rising to $0.67. Total income and other revenues grew by 11.0% to $630.6 million, while net cash provided by operating activities increased by 20.5% to $718.2 million. The company also acquired $452.4 million in financial royalty assets and repurchased $50.1 million of Class A ordinary shares during the quarter, with $1.7 billion remaining under the repurchase program.
Key Highlights
- Net income attributable to Royalty Pharma plc increased 23.1% to $294.7 million.
- Basic earnings per Class A ordinary share rose 21.8% to $0.67.
- Total income and other revenues grew 11.0% to $630.6 million.
- Net cash provided by operating activities increased 20.5% to $718.2 million.
- Acquired $452.4 million in financial royalty assets during the quarter.
- Repurchased 1.1 million Class A ordinary shares for $50.1 million.
- $1.7 billion remained available under the share repurchase program as of March 31, 2026.
- Recognized a financial royalty asset impairment of $69.4 million.